002550 Changzhou Qianhong Biopharma
- 6.18
- +0.17+2.83%
Changzhou Qianhong Biopharma News
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Shareholders Are Still up 52% Over 3 Years Despite Pulling Back 6.5% in the Past Week
Solid Earnings May Not Tell The Whole Story For Changzhou Qianhong BiopharmaLTD (SZSE:002550)
Changzhou Qianhong Biopharma (002550.SZ): It is expected that the sales price of heparin active pharmaceutical ingredient will improve quarter-on-quarter in the fourth quarter.
Changzhou Qianhong Biopharma (002550.SZ) stated at an investor relations event on October 22 that in the third quarter of 2024, the sales volume of heparin active pharmaceutical ingredients increased significantly year-on-year, with gross profit and gross margin at historically high levels. However, export sales prices are still hovering at low levels, and there has been no significant fluctuation in foreign market demand. The number of slaughtered pigs in 2024 decreased by about 10% year-on-year. It is expected that the selling price of heparin active pharmaceutical ingredients will improve quarter-on-quarter in the fourth quarter, possibly showing a stable and upward trend.
Subdued Growth No Barrier To Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) With Shares Advancing 36%
Qianhong Pharmaceutical: Report for the third quarter of 2024
Changzhou Qianhong Biopharma (002550.SZ) announced its performance for the first three quarters, with a net income of 0.31 billion yuan, a year-on-year increase of 56.47%.
Changzhou Qianhong Biopharma (002550.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Changzhou Qianhong Biopharma (002550.SZ): The net income for the third quarter is 0.127 billion yuan, a year-on-year increase of 60.84%.
Gelonghui, October 17th | Changzhou Qianhong Biopharma (002550.SZ) announced its third quarter report of 2024, with a revenue of 0.352 billion yuan, a decrease of 13.97% year-on-year; a net income attributable to shareholders of the listed company of 0.127 billion yuan, an increase of 60.84% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 48.7781 million yuan, a decrease of 9.80% year-on-year; basic earnings per share of 0.1015 yuan.
Qianhong Pharmaceutical: 2024-035 Qianhong Pharmaceutical: Performance forecast for the first three quarters of 2024
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Market Cap up CN¥387m Last Week, Benefiting Both Retail Investors Who Own 49% as Well as Insiders
Changzhou Qianhong Biopharma (002550.SZ): The Qianmu project is scheduled to start production within the year.
Changzhou Qianhong Biopharma (002550.SZ) stated on the investor interaction platform on September 20 that the Qianmu project is currently under intense construction and is planned to be put into operation within this year. The construction of the Qianhong (Hubei) active pharmaceutical ingredient base project is also currently in progress.
Investors Appear Satisfied With Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Prospects
Changzhou Qianhong Biopharma: Summary of Half-Year Report in 2024.
Changzhou Qianhong Biopharma: Half-year report for the year 2024.
Changzhou Qianhong Biopharma (002550.SZ): Net income in the first half of the year reached 0.183 billion yuan, a year-on-year increase of 53.57%.
On August 15, Gelunhui reported that Changzhou Qianhong Biopharma (002550.SZ) published its 2024 interim report, achieving revenue of 0.856 billion yuan and net income attributable to shareholders of listed companies of 0.183 billion yuan in the first half of the year, an increase of 53.57% compared to the same period last year. The net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.179 billion yuan, an increase of 60.64% compared to the same period last year, with basic earnings per share of 0.1457 yuan. The main reason is due to the company's active response to the severe and complex ecological environment of the domestic and foreign pharmaceutical industry, timely grasping industry global strategy opportunities, and implementing scientific and rational production, supply, and marketing.
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has A Pretty Healthy Balance Sheet
Changzhou Qianhong Biopharma: Changzhou Qianhong Biopharma: Performance Forecast for the First Half of 2024.
Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Has Had A Decent Run On The Stock Market: Are Fundamentals In The Driver's Seat?
Income Investors Should Know That Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Goes Ex-Dividend Soon
Investors Appear Satisfied With Changzhou Qianhong Biopharma CO.,LTD's (SZSE:002550) Prospects As Shares Rocket 26%
Qianhong Pharmaceutical (002550.SZ) 2023 equity distribution: 1.2 yuan for every 10 shares
Qianhong Pharmaceutical (002550.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...
No Data
